血清MC-CP、CCL26、DcR3水平在COPD并发OSAS诊断中的临床价值

doi:10.16352/j.issn.1001-6325.2025.01.0076

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (1): 76-80.doi: 10.16352/j.issn.1001-6325.2025.01.0076

血清MC-CP、CCL26、DcR3水平在COPD并发OSAS诊断中的临床价值

陈丽萍^1*, 史永兴², 陈艳红¹, 冯平¹, 张长洪¹, 林卫佳¹, 项保利¹

河北北方学院附属第一医院 1.呼吸与危重症医学科; 2.病案管理科,河北张家口 075000

收稿日期:2024-03-15 修回日期:2024-05-29 出版日期:2025-01-05 发布日期:2024-12-25
通讯作者: ^*chen0040888@163.com
基金资助:
张家口市科学技术局2021年市级科技计划自筹经费项目(2121162D)

Clinical value of serum levels of MC-CP, CCL26 and DcR3 in the diagnosis of COPD complicated with OSAS

CHEN Liping^1*, SHI Yongxing², CHEN Yanhong¹, FENG Ping¹, ZHANG Changhong¹, LIN Weijia¹, XIANG Baoli¹

1. Department of Respiratory and Critical Care Medicine; 2. Department of Medical Record Management, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China

Received:2024-03-15 Revised:2024-05-29 Online:2025-01-05 Published:2024-12-25
Contact: ^*chen0040888@163.com

摘要/Abstract

摘要： 目的探究血清肥大细胞羧肽酶(MC-CP)、趋化因子26(CCL26)、诱饵受体3(DcR3)水平在慢性阻塞性肺疾病(COPD)并发阻塞性睡眠呼吸暂停综合征(OSAS)诊断中的临床价值。方法选取2021年1月至2023年1月河北北方学院附属第一医院收治的COPD患者90例,其中单纯COPD患者48例即为COPD组,COPD合并OSAS患者42例即为COPD-OSAS组。同期选取在河北北方学院附属第一医院体检健康志愿者48例为对照组。采用酶联免疫吸附试验(ELISA)检测血清MC-CP、CCL26、DcR3水平。受试者工作特征(ROC)和曲线下面积(AUC)分析血清MC-CP、CCL26、DcR3水平在COPD并发OSAS诊断中的临床价值。多因素Logistic回归分析COPD并发OSAS的影响因素。结果与对照组相比,COPD组和COPD-OSAS组患者吸烟指数、C反应蛋白(CRP)、白细胞计数(WBC)水平依次显著升高,1秒钟用力呼气容积与用力肺活量的比(FEV1/FVC)依次显著降低(P＜0.05);与对照组相比,COPD组和COPD-OSAS组患者MC-CP、CCL26、DcR3水平依次显著升高(P＜0.05);血清MC-CP、CCL26、DcR3 3者联合对COPD并发OSAS诊断的AUC比单独诊断的更高(Z=4.066,P＜0.001;Z=2.391,P＜0.05;Z=2.353,P＜0.05)。多因素Logistic回归分析显示,吸烟指数、MC-CP、CCL26、DcR3水平是COPD并发OSAS的影响因素(P＜0.05)。结论 COPD并发OSAS患者血清中MC-CP、CCL26、DcR3表达水平升高,三者联合可提高对COPD并发OSAS的诊断价值。

关键词: 肥大细胞羧肽酶, 趋化因子26, 诱饵受体3, 慢性阻塞性肺疾病, 阻塞性睡眠呼吸暂停综合征

Abstract: Objective To investigate the clinical value of serum mast cell carboxypeptidase (MC-CP), C-C motif chemokine 26 (CCL26), and decoy receptor 3 (DcR3) in the diagnosis of obstructive sleep apnea syndrome (OSAS) in chronic obstructive pulmonary disease (COPD). Methods Ninety COPD patients who visited the First Affiliated Hospital of Hebei North University from January 2021 to January 2023 were collected. Among them, 48 patients with simple COPD were included in the COPD group, and 42 patients with COPD combined with OSAS were included in the COPD-OSAS group. During the same period, 48 healthy volunteers who underwent physical examination in that Hospital of Hebei North collected as the control group. Enzyme linked immunosorbent assay (ELISA) was applied to detect serum level of MC-CP, CCL26, and DcR3. Receiver operating characteristic (ROC) curve was applied to analyze the clinical value of serum level of MC-CP, CCL26, and DcR3 in the diagnosis of COPD complicated with OSAS. Multivariate Logistic regression was applied to analyze the influencing factors of COPD complicated with OSAS. Results Compared with the control group, the smoking index, C-reactive protein (CRP)and white blood cell count (WBC) in the COPD and COPD-OSAS groups increased obviously in sequence, the ratio of forced expiratory volume in first second to forced vital capacity (FEV1/FVC) decreased obviously in sequence (P＜0.05); Compared with the control group, the level of MC-CP, CCL26, and DcR3 in patients with COPD and COPD-OSAS increased significantly in sequence (P＜0.05); The combination of serum MC-CP, CCL26 and DcR3 had a higher area under the curve(AUC) for the diagnosis of COPD complicated with OSAS compared to the individual diagnosis (Z=4.066, P＜0.001; Z=2.391, P＜0.05; Z=2.353, P＜0.05). Multivariate Logistic regression analysis showed that smoking index, serum level of MC-CP, CCL26 and DcR3 were influencing factors for COPD complicated with OSAS (P＜0.05). Conclusions The simultaneously increased expression of MC-CP, CCL26 and DcR3 in the serum of COPD may support clinical diagnostic of COPD patients with OSAS.

Key words: mast cell carboxypeptidase, C-C motif chemokine 26, decoy receptor 3, chronic obstructive pulmonary disease, obstructive sleep apnea syndrome

中图分类号:

R563.6

陈丽萍, 史永兴, 陈艳红, 冯平, 张长洪, 林卫佳, 项保利. 血清MC-CP、CCL26、DcR3水平在COPD并发OSAS诊断中的临床价值[J]. 基础医学与临床, 2025, 45(1): 76-80.

CHEN Liping, SHI Yongxing, CHEN Yanhong, FENG Ping, ZHANG Changhong, LIN Weijia, XIANG Baoli. Clinical value of serum levels of MC-CP, CCL26 and DcR3 in the diagnosis of COPD complicated with OSAS[J]. Basic & Clinical Medicine, 2025, 45(1): 76-80.

参考文献

[1] Gao J, Wang H, Liu X, et al. Surgical site wound infection, and other postoperative problems after coronary artery bypass grafting in subjects with chronic obstructive pulmonary disease: a Meta-analysis[J]. Int Wound J, 2023, 20:302-312.
[2] 陈凤,冷玉芳,任以行,等.表观遗传调控在阻塞性睡眠呼吸暂停综合征中的作用研究进展[J].基础医学与临床, 2021, 41:899-903.
[3] 何丽.慢性阻塞性肺疾病并发阻塞性睡眠呼吸暂停综合征危险因素相关研究进展[J].中文科技期刊数据库(引文版)医药卫生, 2022, 4:16-19.
[4] Fritzsching B, Contoli M, Porsbjerg C,et al. Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study[J]. Lancet Reg Health Eur, 2021, 13:100275-100284.
[5] 郑洁,邵素菊,何竹青.针灸“肺俞”“大椎”“风门”对哮喘模型大鼠肺组织中嗜酸性粒细胞凋亡的影响[J].中医药信息, 2021, 38:38-42.
[6] 陈炯,胡丕波,邬高华,等.诱饵受体3及肿瘤坏死因子配体相关分子1A在CD4和CD8双阴性T细胞治疗裸鼠胰腺癌种植瘤中的作用[J].中华胰腺病杂志, 2021, 21:20-24.
[7] 陈亚红摘译,王辰点评.2015年更新版GOLD慢性阻塞性肺疾病诊断,治疗和预防的全球策略简介[J]. 中国医学前沿杂志(电子版), 2015, 6:34-39.
[8] 中华医学会呼吸病学分会睡眠呼吸障碍学组.阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版)[J].中华结核和呼吸杂志, 2012, 35:1-4.
[9] 李勇,范丽娜.血液净化对慢性肾衰并发阻塞性睡眠呼吸暂停综合征患者生活质量的影响[J].医学临床研究, 2016, 33:2225-2226.
[10] 姬峰,韩其政,亓梅,等.老年支气管哮喘患者血清MC-CP,S1P水平与T细胞免疫分子及气道基底膜厚度的关系[J].现代生物医学进展, 2020, 20:3883-3887.
[11] 刘雯,费维伦,梁春阳,等.血清DcR3对COPD急性加重期患者预后评估的应用价值[J].中国急救复苏与灾害医学杂志, 2022, 17:225-229.
[12] 段菲,闵春燕,孙小卫,等.老年慢性阻塞性肺疾病患者发生衰弱的影响因素及其风险预测列线图模型构建[J].实用心脑肺血管病杂志, 2022, 30:64-69.

血清MC-CP、CCL26、DcR3水平在COPD并发OSAS诊断中的临床价值

Clinical value of serum levels of MC-CP, CCL26 and DcR3 in the diagnosis of COPD complicated with OSAS

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

[1]	杜敬宇, 应站专, 侯宾, 多杰, 赵振. 抑制miR-34a减轻慢性阻塞性肺疾病急性加重期炎性反应[J]. 基础医学与临床, 2024, 44(12): 1670-1677.
[2]	陈瑜婷, 黄玲, 夏俊杰, 邱宇, 弋可, 王金诚. 转录因子T-bet在慢性阻塞性肺疾病发病中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1322-1325.
[3]	秦玉春, 邝向东, 蔡林再, 谢景臣, 陈山. 双氢青蒿素减轻慢性阻塞性肺疾病(COPD)模型大鼠肺损伤[J]. 基础医学与临床, 2023, 43(3): 427-432.
[4]	夏岑峰, 王娜, 张鹏. 慢性阻塞性肺疾病发病易感性与单核苷酸多态性相关[J]. 基础医学与临床, 2022, 42(12): 1891-1894.
[5]	那扎开提·艾尼瓦尔, 胡广, 张田甜, 宋美月, 赵红梅, 靳洪涛, 王婧. 阿胶对慢性阻塞性肺疾病大鼠肺功能及肺组织病理损伤的影响[J]. 基础医学与临床, 2021, 41(7): 970-974.
[6]	程涛, 马程远, 尹亚楠, 孙贝贝. 依达拉奉减轻慢性阻塞性肺疾病大鼠氧化应激和炎性反应[J]. 基础医学与临床, 2021, 41(10): 1457-1462.
[7]	杨玥, 卞涛. 不同细胞来源的外泌体在COPD中的研究进展[J]. 基础医学与临床, 2020, 40(12): 1721-1726.
[8]	吴晓娟余倩李敏超. 气道内高压力促进3种气道重塑相关因子的表达[J]. 基础医学与临床, 2017, 37(6): 763-767.
[9]	马志明张珍祥韩泽民. 慢性阻塞性肺疾病患者HO-1基因启动子微卫星多态性与iNOS表达关系的研究[J]. 基础医学与临床, 2007, 27(1): 63-67.